GlassScriptPhysician profile
Mohamed S Naem
NPI 1588981195
$708,263.87
in general payments reported to CMS, 2019-2025
38 companies · $207K in 2025
The $207K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $37K · 2021: $37K · 2022: $95K · 2023: $146K · 2024: $160K · 2025: $207K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $370K · Grant: $66K · Travel and Lodging: $45K · Consulting Fee: $19K · Food and Beverage: $13K · Education: $24.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $369,759.86 |
| Grant | $66,000.00 |
| Travel and Lodging | $45,294.72 |
| Consulting Fee | $18,600.00 |
| Food and Beverage | $12,882.04 |
| Education | $24.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299,021.64 | 2019-2025 | |
| Janssen Biotech, INC. | $231,858.58 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $68,809.82 | 2019-2025 | |
| Madrigal Pharmaceuticals | $66,038.50 | 2024-2025 | Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $25,488.37 | 2021-2022 | |
| Pfizer INC. | $6,957.84 | 2019-2025 | |
| Celgene Corporation | $5,442.91 | 2021-2023 | Zeposia |
| Janssen Research & Development, LLC | $1,486.98 | 2020 | |
| Medtronic, INC. | $461.23 | 2021-2025 | Interstim, Eea |
| Takeda Pharmaceuticals U.S.A., INC. | $440.82 | 2019-2025 | Entyvio, Gattex |
| Boston Scientific Corporation | $268.01 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.27 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $195.10 | 2022-2025 | |
| Medtronic USA, INC. | $169.37 | 2020 | |
| Phathom Pharmaceuticals, INC. | $164.76 | 2024-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $152.19 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $140.11 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $132.34 | 2019-2025 | |
| Shionogi INC | $109.98 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $83.07 | 2024-2025 | Iqirvo, Bylvay |
| Ucb, INC. | $69.72 | 2019-2021 | |
| Apollo Endosurgery US INC | $68.88 | 2023 | Orbera Intragastric Balloon System |
| Qol Medical, LLC | $60.49 | 2023-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $49.00 | 2019-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $47.60 | 2024-2025 | Zenpep |
| Amgen INC. | $40.72 | 2021-2023 | Avsola, Amjevita |
| Ardelyx, INC. | $38.11 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $36.11 | 2021-2022 | |
| Celltrion USA INC. | $31.25 | 2024 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $28.26 | 2022-2023 | Rebyota |
| Lilly USA, LLC | $22.06 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $21.46 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.91 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $19.73 | 2024 | Idacio |
| Novo Nordisk INC | $14.59 | 2025 | Wegovy |
| Organon LLC | $13.71 | 2023 | Hadlima, Renflexis |
| Evoke Pharma, INC. | $13.24 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Naem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.